<DOC>
	<DOCNO>NCT01737827</DOCNO>
	<brief_summary>This study find INC280 safe beneficial effect patient advance hepatocellular carcinoma know dysregulation c-MET pathway .</brief_summary>
	<brief_title>Study Efficacy Safety INC280 Patients With Advanced Hepatocellular Carcinoma .</brief_title>
	<detailed_description>This study design Phase II , single arm , open-label , multicenter study evaluate safety efficacy INC280 first-line treatment patient advance hepatocellular carcinoma ( HCC ) eligible disease progression surgical locoregional therapy , c- MET dysregulation . The study include Dose-Determining Part Dose Expansion Part . Pharmacokinetic safety profile INC280 set liver dysfunction determine Dose-Determining Part . The Dose Expansion Part start appropriate dose patient liver dysfunction determine base pharmacokinetics ( PK ) safety data Dose-Determining Part INC280 ongoing clinical study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Confirmed cMET pathway dysregulation . Advanced hepatocellular carcinoma could suitable treatment locoregional therapy progress follow locoregional therapy . Measurable disease determine RECIST version 1.1 . Current cirrhotic status ChildPugh class A encephalopathy . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; = 2 . Other protocoldefined inclusion criterion may apply . Received prior systemic chemotherapy moleculartargeted therapy hepatocellular carcinoma sorafenib . Previous treatment cMET inhibitor hepatocyte growth factor target therapy . Previous local therapy complete less 4 week prior dose , present , acute toxicity &gt; grade 1 . Known active bleeding ( e.g . bleed gastrointestinal ulcer esophageal varix ) within 2 month prior screen history evidence inherit bleed diathesis coagulopathy . Clinically significant venous arterial thrombotic disease within past 6 month . History acute chronic pancreatitis , surgery pancreas risk factor may increase risk pancreatitis . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>INC280 , advance hepatocellular carcinoma , c-MET pathway dysregulation</keyword>
</DOC>